Human Metabolome TechnologiesHuman Metabolome Technologies, Inc.6090東証スタンダードサービス業FY ending Jun 2026, consolidated, J-GAAP

Human Metabolome Technologies FY ending Jun 2020 results

About 100% of Human Metabolome Technologies's sales come from Metabolome analysis, with Biochemical marker making up much of the rest.

It lost about ¥1 for every ¥100 of sales at the operating level.

Where the money goes

For every ¥100 Human Metabolome Technologies sells, how much goes where, and how much is kept.

FY ending Jun 2020

Margin funnel (derived from reported values)Gross margin 76.6% → Operating margin -1.5% → Net margin -4.3%

Revenue by business segment, and the profit each one keeps.

FY ending Jun 2020

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第21期(2023/07/01－2024/06/30)
ID S100UE9D2024-09-24Open
EDINET (FSA Japan)
有価証券報告書－第19期(令和3年7月1日－令和4年6月30日)
ID S100P8152022-09-26Open
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年7月1日－令和3年6月30日)
ID S100MHKD2021-09-27Open

Extracted from XBRL: 37 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.